Low penetration of oseltamivir and its carboxylate into cerebrospinal fluid in healthy Japanese and Caucasian volunteers

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 10, 2008, Pages 3687-3693

  Jhee, S S ^a   Yen, M ^a   Ereshefsky, L ^a   Leibowitz, M ^a   Schulte, M ^b   Kaeser, B ^b   Boak, L ^b   Patel, A ^b   Hoffmann, G ^b   Prinssen, E P ^b   Rayner, C R ^b,c  

^a CALIFORNIA CLINICAL TRIALS   (United States)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; OSELTAMIVIR;

ABNORMAL BEHAVIOR; ADULT; AREA UNDER THE CURVE; ARTICLE; BACKACHE; CAUCASIAN; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG TOLERABILITY; HEADACHE; HUMAN; HUMAN EXPERIMENT; INFLUENZA; JAPANESE; MALE; MAXIMUM PLASMA CONCENTRATION; MUSCULOSKELETAL STIFFNESS; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; THORAX PAIN; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

ADMINISTRATION, ORAL; ADULT; ANTIVIRAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CENTRAL NERVOUS SYSTEM; ENZYME INHIBITORS; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; INFLUENZA, HUMAN; MALE; NEURAMINIDASE; ORTHOMYXOVIRIDAE; OSELTAMIVIR;

EID: 54049128514     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00327-08     Document Type: Article

References (35)

1. Bleasby, K., L. A. Hall, J. L. Perry, H. W. Mohrenweiser, and J. B. Pritchard. 2005. Functional consequences of single nucleotide polymorphisms in the human organic anion transporter hOAT1 (SLC22A6). J. Pharmacol. Exp. Ther. 314:923-931.
2. Blumentals, W. A., and X. Song. 2007. The safety of oseltamivir in patients with influenza: analysis of healthcare claims data from six influenza seasons. Med. Gen. Med. 9:23.
3. Ereshefsky, L., S. S. Jhee, M. T. Leibowitz, S. Moran, M. Yen, and L. Gertsik. 2006. Demonstrating proof of principle and finding the right dose: the role of CSF 'Dynabridging' studies. Abstr. 25th Bienn. Congr. Coll. Int. Neuro-Psychopharmacol. (CINP), Chicago, IL.
4. Fujita, T., C. Brown, E. J. Carlson, T. Taylor, M. de la Cruz, S. J. Johns, D. Stryke, M. Kawamoto, K. Fujita, R. Castro, C. W. Chen, E. T. Lin, C. M. Brett, E. G. Burchard, T. E. Ferrin, C. C. Huang, M. K. Leabman, and K. M. Giacomini. 2005. Functional analysis of polymorphisms in the organic anion transporter, SLC22A6 (OAT1). Pharmacogenet. Genomics 15:201-209.
5. Fuke, C., Y. Ihama, and T. Miyazaki. 2008. Analysis of oseltamivir active metabolite, oseltamivir carboxylate, in biological materials by HPLC-UV in a case of death following ingestion of Tamiflu. J. Leg. Med. (Tokyo) 10:83-87.
6. Fukumoto, Y., A. Okumura, F. Hayakawa, M. Suzuki, T. Kato, K. Watanabe, and T. Morishima. 2007. Serum levels of cytokines and EEG findings in children with influenza associated with mild neurological complications. Brain Dev. 29:425-430.
7. Gieschke, R., R. Dutkowski, J. Smith, and C. R. Rayner. 2007. Similarity in the pharmacokinetics of oseltamivir and oseltamivir carboxylate in Japanese and Caucasian children. Abstr. Options Control Influenza VI, Toronto, Ontario, Canada, abstr. P921.
8. Goshima, N., T. Nakano, M. Nagao, and T. Ihara. 2006. Clinical study of abnormal behavior during influenza. Infect. Immun. Childhood 18:376.
9. Hayden, F. G., R. Belshe, C. Villanueva, R. Lanno, C. Hughes, I. Small, R. Dutkowski, P. Ward, and J. Carr. 2004. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J. Infect. Dis. 189:440-449.
10. He, G., J. Massarella, and P. Ward. 1999. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin. Pharmacokinet. 37:471-484.
11. Hill, G., T. Cihlar, C. Oo, E. S. Ho, K. Prior, H. Wiltshire, J. Barrett, B. Liu, and P. Ward. 2002. The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. Drug Metab. Dispos. 30:13-19.
12. Huang, Y. C., T. Y. Lin, S. L. Wu, and K. C. Tsao. 2003. Influenza A-associated central nervous system dysfunction in children presenting as transient visual hallucination. Pediatr. Infect. Dis. J. 22:366-368.
13. Ishikawa, T., H. Hirano, Y. Onishi, A. Sakurai, and S. Tarui. 2004. Functional evaluation of ABCB1 (P-glycoprotein) polymorphisms: high-speed screening and structure-activity relationship analyses. Drug Metab. Pharmacokinet. 19:1-14.
14. Jhee, S. S., and V. Zarotsky. 2003. Safety and tolerability of serial cerebrospinal fluid (CSF) collections during pharmacokinetic/ pharmacodynamic studies: 5 years' experience. Clin. Res. Regul. Aff. 20:357-363.
15. Kikuchi, R., H. Kusuhara, T. Abe, H. Endou, and Y. Sugiyama. 2004. Involvement of multiple transporters in the efflux of 3-hydroxy-3- methylglutaryl-CoA reductase inhibitors across the blood-brain barrier. J. Pharmacol. Exp. Ther. 311:1147-1153.
16. Kikuchi, R., H. Kusuhara, D. Sugiyama, and Y. Sugiyama. 2003. Contribution of organic anion transporter 3 (Slc22a8) to the elimination of p-aminohippuric acid and benzylpenicillin across the blood-brain barrier. J. Pharmacol. Exp. Ther. 306:51-58.
17. Lin, C. H., Y. C. Huang, C. H. Chiu, C. G. Huang, K. C. Tsao, and T. Y. Lin. 2006. Neurologic manifestations in children with influenza B virus infection. Pediatr. Infect. Dis. J. 25:1081-1083.
18. Lindemann, L., H. Jacobsen, C. Schweitzer, C. Schuhbauer, D. Reinhardt, C. Fischer, C. Diener, S. Gatti, J. Beck, J. G. Wettstein, H. Loetscher, E. Prinssen, and M. Brockhaus. 2008. Comprehensive in vitro pharmacological selectivity profile of oseltamivir prodrug (Tamiflu) and oseltamivir active metabolite. Abstr. Exp. Biol., San Diego, CA, abstr. LB671.
19. Marzolini, C., R. G. Tirona, and R. B. Kim. 2004. Pharmacogenomics of the OATP and OAT families. Pharmacogenomics J. 5:273-282.
20. Morimoto, K., M. Nakakariya, Y. Shirasaka, C. Kakinuma, T. Fujita, I. Tamai, and T. Ogihara. 2008. Oseltamivir (Tamiflu) efflux transport at the blood-brain barrier via P-glycoprotein. Drug Metab. Dispos. 36:6-9.
21. Moscona, A. 2005. Neuraminidase inhibitors for influenza. N. Engl. J. Med. 353:1363-1373.
22. Nicholson, K. G., F. Y. Aoki, A. D. Osterhaus, S. Trottier, O. Carewicz, C. H. Mercier, A. Rode, N. Kinnersley, P. Ward, et al. 2000. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Lancet 355:1845-1850.
23. Okumura, A., T. Kubota, T. Kato, and T. Morishima. 2006. Oseltamivir and delirious behavior in children with influenza. Pediatr. Infect. Dis. J. 25:572.
24. Okumura, A., T. Nakano, Y. Fukumoto, K. Higuchi, H. Kamiya, K. Watanabe, and T. Morishima. 2005. Delirious behavior in children with influenza: its clinical features and EEG findings. Brain Dev. 27:271-274.
25. Ose, A., H. Kusuhara, K. Yamatsugu, M. Kanai, M. Shibasaki, T. Fujita, A. Yamamoto, and Y. Sugiyama. 2008. P-glycoprotein restricts the penetration of oseltamivir across the blood-brain barrier. Drug Metab. Dispos. 36:427-434.
26. Peters, P. H., Jr., S. Gravenstein, P. Norwood, V. De Bock, A. Van Couter, M. Gibbens, T. A. von Planta, and P. Ward. 2001. Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. J. Am. Geriatr. Soc. 49:1025-1031.
27. Sakurai, A., A. Tamura, Y. Onishi, and T. Ishikawa. 2005. Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCG2: therapeutic implications. Expert Opin. Pharmacother. 6:2455-2473.
28. Schentag, J., G. Hill, T. Chu, and C. Rayner. 24 April 2007. Similarity in pharmacokinetics of oseltamivir and oseltamivir carboxylate in Japanese and Caucasian subjects. J. Clin. Pharmacol. 47:689-696. [Epub ahead of print.]
29. Shen, D. D., A. A. Artru, and K. K. Adkison. 2004. Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics. Adv. Drug Deliv. Rev. 56:1825-1857.
30. Shi, D., J. Yang, D. Yang, E. L. Lecluyse, C. Black, L. You, F. Akhlaghi, and B. Yan. 2006. Anti-influenza prodrug oseltamivir is activated by carboxylesterase HCE1, and the activation is inhibited by antiplatelet agent clopidogrel. J. Pharmacol. Exp. Ther. 319:1477-1484.
31. Straumanis, J. P., M. D. Tapia, and J. C. King. 2002. Influenza B infection associated with encephalitis: treatment with oseltamivir. Pediatr. Infect. Dis. J. 21:173-175.
32. Toovey, S., C. R. Rayner, E. Prinssen, T. Chu, B. Donner, R. Dutkowski, S. Sacks, J. Solsky, I. Small, and D. Reddy. 2008. Post-marketing safety assessment of neuropsychiatric adverse event risk in patients with influenza treated with oseltamivir. Abstr. X Int. Symp. Respir. Viral Infect., Singapore City, Singapore.
33. Whitley, R. J., F. G. Hayden, K. S. Reisinger, N. Young, R. Dutkowski, D. Ipe, R. G. Mills, and P. Ward. 2001. Oral oseltamivir treatment of influenza in children. Pediatr. Infect. Dis. J. 20:127-133.
34. Wilcox, M., and S. Zhu. 2007. Oseltamivir therapy appears not to affect the incidence of neuropsychiatric adverse events in influenza patients. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL, abstr. V-1223a.
35. Wiltshire, H., B. Wiltshire, A. Citron, T. Clarke, C. Serpe, D. Gray, and W. Herron. 2000. Development of a high-performance liquid chromatographicmass spectrometric assay for the specific and sensitive quantification of Ro 64-0802, an anti-influenza drug, and its pro-drug, oseltamivir, in human and animal plasma and urine. J. Chromatogr. B 745:373-388.